Ezio Bonvini's Insider Trades & SAST Disclosures
Ezio Bonvini's most recent trade in Macrogenics Inc was a trade of 16,665 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Ezio Bonvini.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,665 | 16,665 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,665 | 124,414 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 128,000 | 128,000 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 21,000 | 21,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 11,168 | 112,060 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 11,168 | 22,332 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.60 per share. | 07 Feb 2025 | 4,311 | 107,749 (0%) | 0% | 2.6 | 11,209 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 28,125 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 28,125 | 110,258 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.11 per share. | 22 Feb 2024 | 9,366 | 100,892 (0%) | 0% | 17.1 | 160,252 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 16,670 | 88,004 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 16,670 | 33,330 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.40 per share. | 15 Feb 2024 | 5,871 | 82,133 (0%) | 0% | 17.4 | 102,155 | Common Stock |
| Macrogenics Inc | Bonvini Ezio | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 33,500 | 33,500 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 07 Feb 2024 | 3,334 | 71,334 (0%) | 0% | 18 | 60,012 | Common Stock |
| Macrogenics Inc | Bonvini Ezio | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 01 Feb 2024 | 13,316 | 74,668 (0%) | 0% | 15 | 199,740 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 19 Jan 2024 | 13,316 | 87,984 (0%) | 0% | 12 | 159,792 | Common Stock |
| Macrogenics Inc | Bonvini Ezio | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 10.08 per share. | 20 Dec 2023 | 18,880 | 101,300 (0%) | 0% | 10.1 | 190,310 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 9,375 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 9,375 | 123,799 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.55 per share. | 22 Feb 2023 | 3,619 | 120,180 (0%) | 0% | 6.5 | 23,704 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 200,000 | 200,000 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 50,000 | 50,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2022 | 5,000 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2022 | 5,000 | 116,090 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.16 per share. | 14 May 2022 | 1,666 | 114,424 (0%) | 0% | 4.2 | 6,931 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 75,000 | 75,000 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 37,500 | 37,500 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 16 Nov 2021 | 2,540 | 111,090 (0%) | 0% | 16 | 40,640 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 2,540 | 0 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 21,855 | 2,540 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 24 Jun 2021 | 21,855 | 104,329 (0%) | 0% | 16 | 349,680 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.53 per share. | 24 Jun 2021 | 4,221 | 108,550 (0%) | 0% | 20.5 | 86,657 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 4,221 | 63,279 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2021 | 5,000 | 5,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2021 | 5,000 | 84,890 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.49 per share. | 14 May 2021 | 2,416 | 82,474 (0%) | 0% | 29.5 | 71,248 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 22 Mar 2021 | 3,917 | 79,890 (0%) | 0% | 32 | 125,344 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 120,000 | 120,000 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 29.88 per share. | 17 Sep 2020 | 44,512 | 102,146 (0%) | 0% | 29.9 | 1,330,019 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 17 Sep 2020 | 18,339 | 83,807 (0%) | 0% | 32 | 586,848 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges